Simulations Plus

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SLP and other ETFs, options, and stocks.

About SLP

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. 

CEO
Shawn M. O'Connor
CEOShawn M. O'Connor
Employees
213
Employees213
Headquarters
Durham, North Carolina
HeadquartersDurham, North Carolina
Founded
1996
Founded1996
Employees
213
Employees213

SLP Key Statistics

Market cap
313.89M
Market cap313.89M
Price-Earnings ratio
-4.86
Price-Earnings ratio-4.86
Dividend yield
Dividend yield
Average volume
578.75K
Average volume578.75K
High today
$15.69
High today$15.69
Low today
$14.27
Low today$14.27
Open price
$15.47
Open price$15.47
Volume
367.26K
Volume367.26K
52 Week high
$36.45
52 Week high$36.45
52 Week low
$11.09
52 Week low$11.09

Stock Snapshot

With a market cap of 313.89M, Simulations Plus(SLP) trades at $14.27. The stock has a price-to-earnings ratio of -4.86.

On 2026-04-23, Simulations Plus(SLP) stock moved within a range of $14.27 to $15.69. With shares now at $14.27, the stock is trading 0.0% above its intraday low and -9.1% below the session's peak.

Trading activity shows a volume of 367.26K, compared to an average daily volume of 578.75K.

The stock's 52-week range extends from a low of $11.09 to a high of $36.45.

The stock's 52-week range extends from a low of $11.09 to a high of $36.45.

SLP News

TipRanks 2d
Simulations Plus enters funded research collaboration with Lonza, FDA

Simulations Plus (SLP) announced a funded research collaboration with Lonza Group (LZAGY) and the U.S. Food and Drug Administration to develop and validate a me...

TipRanks 3d
Simulations Plus announces completion of 2026 Spring School

Simulations Plus (SLP) announced the completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug develop...

Analyst ratings

57%

of 7 ratings
Buy
42.9%
Hold
57.1%
Sell
0%

People also own

Based on the portfolios of people who own SLP. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.